Journal article
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer
Abstract
Second-line therapy options that improve survival for patients with advanced non-small-cell lung cancer (NSCLC) are needed. This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in combination with pemetrexed compared with pemetrexed monotherapy in patients with NSCLC whose disease had progressed after previous platinum-based chemotherapy. The combination of volasertib with pemetrexed did not improve efficacy compared …
Authors
Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K
Journal
Clinical Lung Cancer, Vol. 16, No. 6, pp. 457–465
Publisher
Elsevier
Publication Date
11 2015
DOI
10.1016/j.cllc.2015.05.010
ISSN
1525-7304
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCell Cycle ProteinsDrug Dosage CalculationsDrug InteractionsDrug Resistance, NeoplasmDrug Therapy, CombinationFatigueFemaleHumansLung NeoplasmsMaleMiddle AgedNauseaPemetrexedPlatinum CompoundsProtein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesSurvival AnalysisPolo-Like Kinase 1